These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 17563732)

  • 21. Myeloablative conditioning is well tolerated by older patients receiving T-cell-depleted grafts.
    Novitzky N; Thomas V; Hale G; Waldmann H
    Bone Marrow Transplant; 2005 Oct; 36(8):675-82. PubMed ID: 16113675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation.
    Orti G; Lowdell M; Fielding A; Samuel E; Pang K; Kottaridis P; Morris E; Thomson K; Peggs K; Mackinnon S; Chakraverty R
    Transplantation; 2009 Dec; 88(11):1312-8. PubMed ID: 19996931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myeloablative allogeneic stem cell transplantation for advanced stage multiple myeloma: very long-term follow up of a single center experience.
    Kennedy GA; Butler J; Morton J; Hill G; Western R; Cummings J; Allison R; Durrant S
    Clin Lab Haematol; 2006 Jun; 28(3):189-97. PubMed ID: 16706936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allogeneic transplantation for multiple myeloma: late relapse may occur as localised lytic lesion/plasmacytoma despite ongoing molecular remission.
    Byrne JL; Fairbairn J; Davy B; Carter IG; Bessell EM; Russell NH
    Bone Marrow Transplant; 2003 Feb; 31(3):157-61. PubMed ID: 12621475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma.
    Toporski J; Garkavij M; Tennvall J; Ora I; Gleisner KS; Dykes JH; Lenhoff S; Juliusson G; Scheding S; Turkiewicz D; Békássy AN
    Biol Blood Marrow Transplant; 2009 Sep; 15(9):1077-85. PubMed ID: 19660720
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation.
    Lutz C; Massenkeil G; Nagy M; Neuburger S; Tamm I; Rosen O; Dörken B; Arnold R
    Bone Marrow Transplant; 2008 May; 41(9):805-12. PubMed ID: 18195682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
    Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma.
    Bloor AJ; Thomson K; Chowdhry N; Verfuerth S; Ings SJ; Chakraverty R; Linch DC; Goldstone AH; Peggs KS; Mackinnon S
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):50-8. PubMed ID: 18158961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The allogeneic dilemma.
    Harousseau JL
    Bone Marrow Transplant; 2007 Dec; 40(12):1123-8. PubMed ID: 17680016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduced-intensity conditioning regimen preserves thymic function in the early period after hematopoietic stem cell transplantation.
    Jiménez M; Martínez C; Ercilla G; Carreras E; Urbano-Ispízua A; Aymerich M; Villamor N; Amézaga N; Rovira M; Fernández-Avilés F; Gaya A; Martino R; Sierra J; Montserrat E
    Exp Hematol; 2005 Oct; 33(10):1240-8. PubMed ID: 16219547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-centre experience with nonmyeloablative allogeneic stem cell transplantation in patients with multiple myeloma: prolonged remissions induced.
    van Dorp S; Meijer E; van de Donk NW; Dekker AW; Nieuwenhuis K; Minnema MC; Petersen E; Schutgens R; Verdonck LF; Lokhorst HM
    Neth J Med; 2007 May; 65(5):178-84. PubMed ID: 17519513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Non-myeloablative allogeneic stem cell transplantation].
    Dalgaard J; Fløisand Y; Stenersen M; Egeland T; Brinch L
    Tidsskr Nor Laegeforen; 2007 Mar; 127(6):721-4. PubMed ID: 17363982
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation.
    Russell NH; Byrne JL; Faulkner RD; Gilyead M; Das-Gupta EP; Haynes AP
    Bone Marrow Transplant; 2005 Sep; 36(5):437-41. PubMed ID: 15980879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD8+ cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot study.
    Alyea EP; Canning C; Neuberg D; Daley H; Houde H; Giralt S; Champlin R; Atkinson K; Soiffer RJ
    Bone Marrow Transplant; 2004 Jul; 34(2):123-8. PubMed ID: 15133487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of disseminated adenovirus infections using quantitative plasma PCR in adult allogeneic stem cell transplant recipients receiving reduced intensity or myeloablative conditioning.
    Kalpoe JS; van der Heiden PL; Barge RM; Houtzager S; Lankester AC; van Tol MJ; Kroes AC
    Eur J Haematol; 2007 Apr; 78(4):314-21. PubMed ID: 17331130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
    Shigematsu A; Kondo T; Yamamoto S; Sugita J; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Obara M; Wakasa K; Takahata M; Takeda Y; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
    Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.
    Kröger N; Badbaran A; Zabelina T; Ayuk F; Wolschke C; Alchalby H; Klyuchnikov E; Atanackovic D; Schilling G; Hansen T; Schwarz S; Heinzelmann M; Zeschke S; Bacher U; Stübig T; Fehse B; Zander AR
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):398-404. PubMed ID: 23078786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcome of allogeneic stem cell transplantation in children with non-malignant diseases.
    Willasch A; Hoelle W; Kreyenberg H; Niethammer D; Handgretinger R; Lang P; Beck JF; Klingebiel T; Bader P
    Haematologica; 2006 Jun; 91(6):788-94. PubMed ID: 16769581
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma.
    El-Cheikh J; Crocchiolo R; Furst S; Ladaique P; Castagna L; Faucher C; Granata A; Oudin C; Lemarie C; Calmels B; Stoppa AM; Schiano De Colella JM; Duran S; Chabannon C; Blaise D
    Exp Hematol; 2012 Jul; 40(7):521-7. PubMed ID: 22446605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.